Marshall Schreeder, MD
Medical Oncology · Huntsville, ALNPI 1083693154
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,420 of the $7,631 with a category attached, or 84.1%. It is spread thinly across 60 manufacturers, the largest accounting for just 7.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,117, 3.0 times the $704 reported in 2019.
Across 303 payments — averaging $25.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$578
- AbbVie$572
- Novartis$564
- Seagen Inc.$498
- Welch Allyn$432
- AstraZeneca$430
- plus $5K from 54 others
Across 367 payments — averaging $3026.19 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$778K
- TG Therapeutics, Inc.$233K
- Janssen Research & Development, LLC$32K
- Orphai Therapeutics Inc.$21K
- Gilead$20K
- AstraZeneca$11K
- plus $16K from 3 others
What the payments were for
- Speaking & faculty fees$1202%
- Grants$5017%
- Food & beverage$6,42084%
- Education$1582%
- Other$4326%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,631 in reported general payments places this provider in the 55th percentile of 30 medical oncology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CabometyxCabozantinib S-Malate | 31 | $930,739 |
| RevlimidLenalidomide | 37 | $723,823 |
| IbrancePalbociclib | 55 | $587,327 |
| XtandiEnzalutamide | 50 | $564,971 |
| VerzenioAbemaciclib | 42 | $540,890 |
| JakafiRuxolitinib Phosphate | 29 | $415,068 |
| NeulastaPegfilgrastim | 43 | $265,247 |
| ErleadaApalutamide | 19 | $250,957 |
| Lenalidomide | 11 | $204,797 |
| BrukinsaZanubrutinib | 13 | $188,231 |
| CalquenceAcalabrutinib Maleate | 11 | $150,201 |
| Udenyca AutoinjectorPegfilgrastim-Cbqv | 34 | $131,521 |
| TrazimeraTrastuzumab-Qyyp | 30 | $129,360 |
| EliquisApixaban | 150 | $112,684 |
| Sunitinib Malate | 12 | $63,069 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerIbrance, Trazimera, Eliquis | $578 | $829,371235 claims |
| Bristol Myers SquibbRevlimid | $168 | $723,82337 claims |
| Astellas Pharma US IncXtandi | $24 | $564,97150 claims |
| Lilly USA, LLCVerzenio, Olanzapine | $23 | $541,371133 claims |
| Incyte CorporationJakafi | $212 | $415,06829 claims |
| Johnson & JohnsonErleada, Xarelto | $286 | $275,60048 claims |
| AmgenNeulasta | $148 | $265,24743 claims |
| Beigene USA, Inc.Brukinsa | $36 | $188,23113 claims |
| AstraZenecaCalquence | $430 | $150,20111 claims |
| AbbVieCreon, Venclexta | $572 | $89,34643 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 30 medical oncology providers in Alabama.
Other medical oncology in Huntsville
- John WaplesHuntsville$19K
- Manh DangHuntsville$4K
- Jeremy HonHuntsville$1K
- Joelle HamiltonHomewood$361K
- Syed Abbas AliJasper$51K
- Pranitha ProdduturvarMobile$33K
- Johnny NacillaCullman$23K
- Michael GarciaJasper$23K
- Susan BostickTuscaloosa$17K
- Brittany CaseDaphne$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.